Vantive US Healthcare Recalls Oxiris Set Dialyzers Due to Chamber Dislodgement Risk
Vantive US Healthcare LLC has issued a voluntary recall for 2,724 Oxiris Set dialyzers because the deaeration chamber may dislodge from the control unit.
What Happened
Vantive US Healthcare LLC has initiated a voluntary recall of the Oxiris Set dialyzer system. The recall was prompted by the discovery of a potential defect where the Prismaflex Set deaeration chamber may dislodge from the Prismaflex Control Unit during use.
Which Products Are Affected
The recall involves the following medical device:
- Product Name: OXIRIS SET (Dialyzer, High Permeability With Or Without Sealed Dialysate System)
- Product Code: 112016
- Recall Number: Z-1226-2026
- UDI/DI: 07332414102234
- Lot Information: All lots including and manufactured after 24G0041Z
- Quantity: 2,724 units
- Distribution: Distributed nationwide across the United States.
What You Should Do
The recalling firm, Vantive US Healthcare LLC, initiated the recall process on January 6, 2026, via a notification letter to affected customers. Healthcare facilities and providers in possession of these units should follow the specific instructions provided in the firm’s notification letter regarding the inspection or return of the affected sets. For further inquiries, contact Vantive US Healthcare LLC at their Deerfield, Illinois location.
Why This Matters
This Class II recall indicates that the use of the affected product may cause temporary or medically reversible adverse health consequences. A dislodged deaeration chamber could lead to treatment interruptions or other complications during critical dialysis procedures.
Source
Information provided by the FDA.
Source: FDA Official Notice
Related Articles
Philips North America Recalls Spectral CT 7500 on Rails Over Potential Rotor Part Displacement
FDA · February 25, 2026
Medline Industries Recalls Mercy Circumcision Trays Due to Compromised Packaging
FDA · February 25, 2026
Medline Industries Recalls Reprocessed ViewFlex Xtra ICE Catheters Due to Potential Particle Contamination
FDA · February 25, 2026